Patents-Review.com
🔗 Permalink
Assignee profile:

POXEL SA

City:

Lyons

Country:

France

Published Applications:

12

Last publication date:

2023-09-26

Patent Grants:

12

Last grant date:

2023-09-26

Top Inventors for applications by POXEL SA

These are the the leading inventors for applications assigned to POXEL SA:

Recent patent applications by POXEL SA

POXEL SA based in Lyons, FR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-09-26 ✅ Patent 11,767,317 granted on 2023-09-26
US17360315
Chemistry; metallurgy

Methods of synthesizing enantiopure deuterium-enriched pioglitazone

 #2 | 2022-12-08 ✅ Patent 12,036,226 granted on 2024-07-16
US20220387437A1
Human necessities

Methods of treating subjects having diabetes with chronic kidney disease

 #3 | 2022-07-07 ✅ Patent 11,918,569 granted on 2024-03-05
US20220211682A1
Human necessities

5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same

 #4 | 2022-01-06 ✅ Patent 11,918,567 granted on 2024-03-05
US20220000851A1
Human necessities

Deuterium-enriched pioglitazone

 #5 | 2021-12-30 ✅ Patent 11,319,313 granted on 2022-05-03
US20210403464A1
Chemistry; metallurgy

Crystalline forms of deuterium-enriched pioglitazone

 #6 | 2020-10-08 ✅ Patent 11,617,754 granted on 2023-04-04
US20200316078A1
Human necessities

Methods of treating heart failure with preserved ejection fraction

 #7 | 2020-07-09 ✅ Patent 11,266,652 granted on 2022-03-08
US20200215072A1
Human necessities

Methods of treating subjects having diabetes with chronic kidney disease

 #8 | 2020-06-11 ✅ Patent 10,940,143 granted on 2021-03-09
US20200179360A1
Human necessities

Deuterium-enriched pioglitazone

 #9 | 2020-01-02 ✅ Patent 11,123,336 granted on 2021-09-21
US20200000788A1
Human necessities

5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same

 #10 | 2019-09-05 ✅ Patent 11,141,411 granted on 2021-10-12
US20190269665A1
Human necessities

Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone

 #11 | 2019-01-10 ✅ Patent 10,576,071 granted on 2020-03-03
US20190008842A1
Human necessities

Deuterium-enriched pioglitazone

 #12 | 2018-05-17 ✅ Patent 10,265,305 granted on 2019-04-23
US20180133204A1
Human necessities

5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same

Also check out Poxel SA's (Lyons, France) applicant profile with 11 patent applications submitted.

AssigneeID:

373700 ⎘